{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T00:33:12Z","timestamp":1777163592145,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,25]]},"DOI":"10.7759\/cureus.107708","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T23:38:39Z","timestamp":1777160319000},"source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular Implications of Calcitonin Therapy: A Narrative Review of Mechanisms, Clinical Risks, and Safety Considerations"],"prefix":"10.7759","author":[{"given":"Jyothsna","family":"Goranti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaishnavi","family":"Sabesan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Sapkota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishak","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandesh","family":"Murali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Calcitonin","author":"McLaughlin MB","year":"2025","unstructured":"McLaughlin MB, Awosika AO, Jialal I. Calcitonin. McLaughlin MB, Awosika AO, Jialal I (ed): StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-021-00610-x","article-title":"A meta-analysis of the therapeutic effect of intranasal salmon calcitonin on osteoporosis","volume":"26","author":"Li N","year":"2021","unstructured":"Li N, Gong YC, Chen J. A meta-analysis of the therapeutic effect of intranasal salmon calcitonin on osteoporosis. Eur J Med Res. 2021, 26:140. 10.1186\/s40001-021-00610-x","journal-title":"Eur J Med Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician\u2019s guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman F","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R. Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014, 25:2359-81. 10.1007\/s00198-014-2794-2","journal-title":"Osteoporos Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study","volume":"109","author":"Chesnut CH","year":"2000","unstructured":"Chesnut CH, Silverman S, Andriano K, et al.. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med. 2000, 109:267-276. 10.1016\/S0002-9343(00)00490-3","journal-title":"Am J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.5.6606","article-title":"Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women","volume":"85","author":"Downs RW Jr","year":"2000","unstructured":"Downs RW Jr, Bell NH, Ettinger MP, et al.. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab. 2000, 85:1783-8. 10.1210\/jcem.85.5.6606","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/BF02561369","article-title":"Clinical efficacy of salmon calcitonin in Paget's disease of bone","volume":"49 Suppl 2","author":"Singer FR","year":"1991","unstructured":"Singer FR. Clinical efficacy of salmon calcitonin in Paget's disease of bone. Calcif Tissue Int. 1991, 49 Suppl 2:S7-8. 10.1007\/BF02561369","journal-title":"Calcif Tissue Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake MT","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008, 83:1032-45. 10.4065\/83.9.1032","journal-title":"Mayo Clin Proc"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780231012","article-title":"Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired clinical resistance","volume":"23","author":"Singer FR","year":"1980","unstructured":"Singer FR, Fredericks RS, Minkin C. Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired clinical resistance. Arthritis Rheum. 1980, 23:1148-54. 10.1002\/art.1780231012","journal-title":"Arthritis Rheum"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/8756-3282(95)00276-6","article-title":"Efficacy and safety of drugs for Paget\u2019s disease of bone","volume":"17","author":"Reginster JY","year":"1995","unstructured":"Reginster JY, Lecart MP. Efficacy and safety of drugs for Paget\u2019s disease of bone. Bone. 1995, 17:485-488. 10.1016\/8756-3282(95)00276-6","journal-title":"Bone"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S158718","article-title":"Clinical efficacy of calcitonin compared to diclofenac sodium in chronic nonspecific low back pain with type I Modic changes: a retrospective study","volume":"11","author":"Zhou J","year":"2018","unstructured":"Zhou J, Li T, Li L, Xue Y. Clinical efficacy of calcitonin compared to diclofenac sodium in chronic nonspecific low back pain with type I Modic changes: a retrospective study. J Pain Res. 2018, 11:1335-42. 10.2147\/JPR.S158718","journal-title":"J Pain Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/1744806917720316","article-title":"Mechanisms of the analgesic effect of calcitonin on chronic pain by alteration of receptor or channel expression","volume":"13","author":"Ito A","year":"2017","unstructured":"Ito A, Yoshimura M. Mechanisms of the analgesic effect of calcitonin on chronic pain by alteration of receptor or channel expression. Mol Pain. 2017, 13:1744806917720316. 10.1177\/1744806917720316","journal-title":"Mol Pain"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(02)00702-0","article-title":"Calcitonin in reflex sympathetic dystrophy syndrome and other painful conditions","volume":"30","author":"Appelboom T","year":"2002","unstructured":"Appelboom T. Calcitonin in reflex sympathetic dystrophy syndrome and other painful conditions. Bone. 2002, 30:84-86. 10.1016\/S8756-3282(02)00702-0","journal-title":"Bone"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjan.2019.08.004","article-title":"Calcitonin as an analgesic agent: review of mechanisms of action and clinical applications (Article in Portuguese)","volume":"69","author":"Yazdani J","year":"2019","unstructured":"Yazdani J, Khiavi RK, Ghavimi MA, Mortazavi A, Hagh EJ, Ahmadpour F. Calcitonin as an analgesic agent: review of mechanisms of action and clinical applications (Article in Portuguese). Braz J Anesthesiol. 2019, 69:594-604. 10.1016\/j.bjan.2019.08.004","journal-title":"Braz J Anesthesiol"},{"key":"ref14","article-title":"Calcitonin and calcitonin receptors","volume":"4","author":"Masi L","year":"2007","unstructured":"Masi L, Brandi ML. Calcitonin and calcitonin receptors. Clin Cases Miner Bone Metab. 2007, 4:117-22.","journal-title":"Clin Cases Miner Bone Metab"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1602","article-title":"A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial","volume":"27","author":"Binkley N","year":"2012","unstructured":"Binkley N, Bolognese M, Sidorowicz-Bialynicka A, et al.. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J Bone Miner Res. 2012, 27:1821-9. 10.1002\/jbmr.1602","journal-title":"J Bone Miner Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2174\/157340641202160209102839","article-title":"Calcium handling and arrhythmogenesis","volume":"12","author":"Bompotis GC","year":"2016","unstructured":"Bompotis GC, Pappas LK, Angelidis C, Kossyvakis C, Giannopoulos G, Deftereos S. Calcium handling and arrhythmogenesis. Med Chem. 2016, 12:170-6. 10.2174\/157340641202160209102839","journal-title":"Med Chem"},{"key":"ref17","article-title":"Calcitonin-induced anaphylactic shock. Case report and review of the literature (Article in Italian)","volume":"42","author":"Piccone U","year":"1994","unstructured":"Piccone U, Pala M, Caprari M. Calcitonin-induced anaphylactic shock. Case report and review of the literature (Article in Italian). Minerva Cardioangiol. 1994, 42:435-41.","journal-title":"Minerva Cardioangiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1021\/mp400720w","article-title":"Drug-induced nephrotoxicity: clinical impact and preclinical in vitro models","volume":"11","author":"Tiong HY","year":"2014","unstructured":"Tiong HY, Huang P, Xiong S, Li Y, Vathsala A, Zink D. Drug-induced nephrotoxicity: clinical impact and preclinical in vitro models. Mol Pharm. 2014, 11:1933-48. 10.1021\/mp400720w","journal-title":"Mol Pharm"},{"key":"ref19","article-title":"Nephrotoxic drugs (Article in Croatian)","volume":"70","author":"Popovi\u0107 B","year":"2016","unstructured":"Popovi\u0107 B, \u0160uti\u0107 I, Markovi\u0107 NB. Nephrotoxic drugs (Article in Croatian). Acta Med Croatica. 2016, 70:309-14.","journal-title":"Acta Med Croatica"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(02)00701-9","article-title":"Possible mechanisms of the analgesic action of calcitonin","volume":"30","author":"Azria M","year":"2002","unstructured":"Azria M. Possible mechanisms of the analgesic action of calcitonin. Bone. 2002, 30:80-83. 10.1016\/S8756-3282(02)00701-9","journal-title":"Bone"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/54.1.220S","article-title":"Calcium-regulating hormones in hypertension: vascular actions","volume":"54","author":"Bukoski RD","year":"1991","unstructured":"Bukoski RD, Kremer D. Calcium-regulating hormones in hypertension: vascular actions. Am J Clin Nutr. 1991, 54:220S-6S. 10.1093\/ajcn\/54.1.220S","journal-title":"Am J Clin Nutr"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.4172\/2165-7092.1000158","article-title":"Calcitonin-induced acute pancreatitis: a case report","volume":"5","author":"Berger Z","year":"2015","unstructured":"Berger Z, Cortes C, Cabello H. Calcitonin-induced acute pancreatitis: a case report. Pancreat Disord Ther. 2015, 5:158. 10.4172\/2165-7092.1000158","journal-title":"Pancreat Disord Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jos.2016.12.021","article-title":"Effectiveness of monotherapy and combined therapy with calcitonin and minodronic acid hydrate, a bisphosphonate, for early treatment in patients with new vertebral fractures: an open-label, randomized, parallel-group study","volume":"22","author":"Tanaka S","year":"2017","unstructured":"Tanaka S, Yoshida A, Kono S, Ito M. Effectiveness of monotherapy and combined therapy with calcitonin and minodronic acid hydrate, a bisphosphonate, for early treatment in patients with new vertebral fractures: an open-label, randomized, parallel-group study. J Orthop Sci. 2017, 22:536-41. 10.1016\/j.jos.2016.12.021","journal-title":"J Orthop Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfv011","article-title":"Calcitonin, the forgotten hormone: does it deserve to be forgotten?","volume":"8","author":"Felsenfeld AJ","year":"2015","unstructured":"Felsenfeld AJ, Levine BS. Calcitonin, the forgotten hormone: does it deserve to be forgotten?. Clin Kidney J. 2015, 8:180-7. 10.1093\/ckj\/sfv011","journal-title":"Clin Kidney J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.otorri.2016.09.004","article-title":"Nasal osteoma and inhaled salmon calcitonin: coincidence or consequence?","volume":"68","author":"Pe\u00f1a-Rodr\u00edguez ZA","year":"2017","unstructured":"Pe\u00f1a-Rodr\u00edguez ZA, Haro-Garc\u00eda M, Benito-Navarro JR. Nasal osteoma and inhaled salmon calcitonin: coincidence or consequence?. Acta Otorrinolaringol Esp (Engl Ed). 2017, 68:366-8. 10.1016\/j.otorri.2016.09.004","journal-title":"Acta Otorrinolaringol Esp (Engl Ed)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1177\/1060028013509233","article-title":"Salmon calcitonin use and associated cancer risk","volume":"47","author":"Overman RA","year":"2013","unstructured":"Overman RA, Borse M, Gourlay ML. Salmon calcitonin use and associated cancer risk. Ann Pharmacother. 2013, 47:1675-84. 10.1177\/1060028013509233","journal-title":"Ann Pharmacother"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3339-z","article-title":"Does salmon calcitonin cause cancer? A review and meta-analysis","volume":"27","author":"Wells G","year":"2016","unstructured":"Wells G, Chernoff J, Gilligan JP, Krause DS. Does salmon calcitonin cause cancer? A review and meta-analysis. Osteoporos Int. 2016, 27:13-9. 10.1007\/s00198-015-3339-z","journal-title":"Osteoporos Int"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update","volume":"26","author":"Camacho PM","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, et al.. American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract. 2020, 26:1-46. 10.4158\/GL-2020-0524SUPPL","journal-title":"Endocr Pract"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3890","article-title":"Current use of bisphosphonates in oncology. International Bone and Cancer Study Group","volume":"16","author":"Body JJ","year":"1998","unstructured":"Body JJ, Bartl R, Burckhardt P, et al.. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol. 1998, 16:3890-9. 10.1200\/JCO.1998.16.12.3890","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/468380-cardiovascular-implications-of-calcitonin-therapy-a-narrative-review-of-mechanisms-clinical-risks-and-safety-considerations","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T23:38:41Z","timestamp":1777160321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/468380-cardiovascular-implications-of-calcitonin-therapy-a-narrative-review-of-mechanisms-clinical-risks-and-safety-considerations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.107708","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,25]]}}}